Trial to control the formation of endolymphatic hydrops from the viewpoint of the water homeostasis of the inner ear

IF 1.6 4区医学 Q2 OTORHINOLARYNGOLOGY

Auris Nasus Larynx Pub Date : 2025-02-01 DOI:10.1016/j.anl.2025.01.001

Taizo Takeda , Setsuko Takeda , Akinobu Kakigi

{"title":"Trial to control the formation of endolymphatic hydrops from the viewpoint of the water homeostasis of the inner ear","authors":"Taizo Takeda , Setsuko Takeda , Akinobu Kakigi","doi":"10.1016/j.anl.2025.01.001","DOIUrl":null,"url":null,"abstract":"<div><div>Endolymphatic hydrops, which is one of the pathologic features of Ménière's disease, has been experimentally and clinically confirmed to be influenced by the blood circulation of vasopressin (VP). It is widely acknowledged that VP plays a pivotal role in regulating water homeostasis. It should also be noted that VP is susceptible to a number of external factors, including changes in the environment, dehydration, and fluctuations in atmospheric pressure. Furthermore, VP is a key regulator of the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is a significant neuroendocrine system that plays a role in regulating responses to emotional and physical stress, as well as the sleep/wake cycle (circadian rhythm). It seems that VP is changeable via the HPA axis. It may be beneficial to consider pharmacological normalization of VP as a potential approach to controlling Ménière's disease. Nevertheless, measuring 8-Arg-vasopressin (AVP), the most prevalent variant of VP, poses certain challenges for a number of reasons. Copeptin is co-released with AVP, is relatively stable in the posterior pituitary as well as in blood plasma, and is increasingly being used as an AVP surrogate in clinical diagnostics. It is thought that the use of copeptin as a marker for AVP may help to clarify the clinical features of Ménière's disease.</div><div>In this review, we will consider trials to control the formation of endolymphatic hydrops from the viewpoint of the vasopressin-aquaporin 2 system. Furthermore, we will explore reports on clinical treatment, pharmacological agents, and future prospects.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"52 2","pages":"Pages 137-140"},"PeriodicalIF":1.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Auris Nasus Larynx","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0385814625000033","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Endolymphatic hydrops, which is one of the pathologic features of Ménière's disease, has been experimentally and clinically confirmed to be influenced by the blood circulation of vasopressin (VP). It is widely acknowledged that VP plays a pivotal role in regulating water homeostasis. It should also be noted that VP is susceptible to a number of external factors, including changes in the environment, dehydration, and fluctuations in atmospheric pressure. Furthermore, VP is a key regulator of the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is a significant neuroendocrine system that plays a role in regulating responses to emotional and physical stress, as well as the sleep/wake cycle (circadian rhythm). It seems that VP is changeable via the HPA axis. It may be beneficial to consider pharmacological normalization of VP as a potential approach to controlling Ménière's disease. Nevertheless, measuring 8-Arg-vasopressin (AVP), the most prevalent variant of VP, poses certain challenges for a number of reasons. Copeptin is co-released with AVP, is relatively stable in the posterior pituitary as well as in blood plasma, and is increasingly being used as an AVP surrogate in clinical diagnostics. It is thought that the use of copeptin as a marker for AVP may help to clarify the clinical features of Ménière's disease.

In this review, we will consider trials to control the formation of endolymphatic hydrops from the viewpoint of the vasopressin-aquaporin 2 system. Furthermore, we will explore reports on clinical treatment, pharmacological agents, and future prospects.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Auris Nasus Larynx 医学-耳鼻喉科学

CiteScore

3.40

自引率

5.90%

发文量

169

审稿时长

30 days

期刊介绍： The international journal Auris Nasus Larynx provides the opportunity for rapid, carefully reviewed publications concerning the fundamental and clinical aspects of otorhinolaryngology and related fields. This includes otology, neurotology, bronchoesophagology, laryngology, rhinology, allergology, head and neck medicine and oncologic surgery, maxillofacial and plastic surgery, audiology, speech science. Original papers, short communications and original case reports can be submitted. Reviews on recent developments are invited regularly and Letters to the Editor commenting on papers or any aspect of Auris Nasus Larynx are welcomed. Founded in 1973 and previously published by the Society for Promotion of International Otorhinolaryngology, the journal is now the official English-language journal of the Oto-Rhino-Laryngological Society of Japan, Inc. The aim of its new international Editorial Board is to make Auris Nasus Larynx an international forum for high quality research and clinical sciences.